Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Simcere Pharmaceutical Group (HKSE:02096) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Simcere Pharmaceutical Group's EV-to-EBIT for today is
Simcere Pharmaceutical Group's current Enterprise Value is HK$29,933 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Simcere Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1,770 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Simcere Pharmaceutical Group's EV-to-EBITDA for today is:
Simcere Pharmaceutical Group's current Enterprise Value is HK$29,933 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Simcere Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1,770 Mil.
Simcere Pharmaceutical Group's current Enterprise Value is HK$29,933 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Simcere Pharmaceutical Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$8,499 Mil.
Simcere Pharmaceutical Group's current Enterprise Value is HK$29,933 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Simcere Pharmaceutical Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was HK$2,214 Mil.
Simcere Pharmaceutical Group's current Enterprise Value is HK$29,933 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Simcere Pharmaceutical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1,262 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group Enterprise Value Related Terms
Simcere Pharmaceutical Group Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group Enterprise Value Chart
HKSE:02096 vs ZTS, UTHR: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's Enterprise Value falls into.
Simcere Pharmaceutical Group Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of HK$29,933 Mil mean?
Simcere Pharmaceutical Group (HKSE:02096) has a Enterprise Value of HK$29,933 Mil as of Jul. 25, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Simcere Pharmaceutical Group and its competitors.
Is Simcere Pharmaceutical Group's Enterprise Value too high?
Simcere Pharmaceutical Group's current Enterprise Value is HK$29,933 Mil. Overall, Simcere Pharmaceutical Group has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Enterprise Value compare to ZTS and UTHR?
Simcere Pharmaceutical Group's Enterprise Value of HK$29,933 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Simcere Pharmaceutical Group and its competitors. Simcere Pharmaceutical Group's current Enterprise Value is HK$29,933 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group (HKSE:02096) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$10.74, compared to a current price of HK$12.73 — trading 18.5% above its estimated fair value. The current Enterprise Value is HK$29,933 Mil. Simcere Pharmaceutical Group's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Simcere Pharmaceutical Group (HKSE:02096), the current Enterprise Value is HK$29,933 Mil as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (HKSE:02096) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of HK$12.73 is trading 18.5% above its estimated GF Value™ of HK$10.74.
GuruFocus considers Simcere Pharmaceutical Group to be Modestly Overvalued.
Key valuation signals for HKSE:02096:
Enterprise Value: HK$29,933 Mil
GF Value™: HK$10.74 vs. price of HK$12.73 (18.5% above fair value)
No single metric tells the full story. See the HKSE:02096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score
Get the complete analysis for HKSE:02096
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02096 has been successfully added to your 
